TNF and psoriasis: China's National Medical Products Administration has approved the following two categories of biologics for the treatment of psoriasis: (1) tumor necrosis factor (TNF)‐α inhibitors, including etanercept, infliximab, and adalimumab; and (2) interleukin inhibitors, including ustekinumab, secukinumab, ixekizumab, and guselkulmab.